Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TriSalus Life Sciences, Inc. is a commercial-stage oncology company focused on developing and commercializing technologies designed to improve the delivery of therapeutics to solid tumors, particularly in immuno-oncology. The company operates at the intersection of medical devices and cancer therapeutics, with an emphasis on overcoming biological barriers that limit drug penetration and immune response within tumors.
The company’s core business centers on its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) platform, which is used to enhance localized delivery of therapeutic agents directly into tumors. TriSalus was founded in 2013 and has evolved from an early-stage device innovator into a publicly traded life sciences company following its merger with a special purpose acquisition company in 2023, which resulted in its listing on Nasdaq under the ticker TLSI.
Business Operations
TriSalus operates through two primary business lines: its medical device platform and its immunotherapy development program. The company generates revenue primarily from sales and clinical use of its TriNav® Infusion System, a catheter-based device designed to optimize intratumoral delivery of drugs in interventional oncology procedures.
In parallel, TriSalus advances a pipeline of investigational immunotherapies, most notably SD-101, a toll-like receptor 9 (TLR9) agonist licensed from an external partner and used in combination with the PEDD platform. Operations include clinical development, regulatory activities, and limited commercial distribution, with activities conducted in the United States and through international clinical collaborations. The company does not currently report large-scale manufacturing and relies on third-party manufacturers and research partners.
Strategic Position & Investments
Strategically, TriSalus positions itself as an enabling platform company seeking to partner with pharmaceutical and biotechnology firms to enhance the effectiveness of existing and emerging oncology drugs. Its growth strategy emphasizes expanding clinical evidence supporting PEDD-enabled delivery, pursuing combination therapy trials, and increasing adoption of its device in interventional oncology settings.
The company’s investments have focused on internal research and development rather than large acquisitions. Its most notable strategic asset is the integration of device and drug development within a single platform, allowing it to address tumor microenvironment challenges that limit immunotherapy efficacy. Public disclosures indicate ongoing evaluation of additional therapeutic candidates and potential partnerships, though specific future transactions have not been conclusively verified in public filings.
Geographic Footprint
TriSalus Life Sciences is headquartered in the United States, with its principal executive offices in Colorado. The company’s commercial and clinical activities are primarily U.S.-based, particularly within major cancer centers and hospitals performing interventional oncology procedures.
Internationally, TriSalus maintains a limited but expanding footprint through clinical trials, physician training, and distributor relationships in Europe, Asia, and select other regions. These activities are largely focused on supporting clinical research and early adoption rather than broad commercial penetration.
Leadership & Governance
TriSalus is led by a management team with experience across medical devices, biotechnology, and oncology-focused life sciences. The leadership emphasizes a strategy centered on clinical validation, physician adoption, and disciplined capital allocation to support long-term platform development.
Key executives include:
- Mary T. Szela – Chief Executive Officer
- Brian J. McNamara – Chief Financial Officer
- Jeffrey J. Leeper – Chief Commercial Officer
- Eric L. Blomgren – Chief Technology Officer
- Michael E. Laney – Chief Medical Officer
The company is governed by a board of directors that includes industry executives and investors with backgrounds in healthcare, medical devices, and public company governance.